Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antiviral PROTACs: Opportunity borne with challenge
Jinsen Liang, Yihe Wu, Ke Lan, et al.
Cell Insight (2023) Vol. 2, Iss. 3, pp. 100092-100092
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Yugendar R. Alugubelli, Jing Xiao, Kaustav Khatua, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6495-6507
Open Access | Times Cited: 16
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges
Shaoqing Du, Xueping Hu, Luis Menéndez‐Arias, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101053-101053
Closed Access | Times Cited: 13
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116202-116202
Open Access | Times Cited: 8
Molecular glue degraders: exciting opportunities for novel drug discovery
Thomas Lemaître, Marie Cornu, Florian Schwalen, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 433-449
Closed Access | Times Cited: 7
Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer
Lilan Xin, Chao Wang, Yan Cheng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8913-8931
Closed Access | Times Cited: 7
Small Molecule Drugs Targeting Viral Polymerases
Deborah Palazzotti, Martina Sguilla, Giuseppe Manfroni, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 661-661
Open Access | Times Cited: 6
Discovery of novel benzosultam CRBN ligands
Hoyeong Park, Santosh Shivanand Raikar, Yonghyo Kim, et al.
Bulletin of the Korean Chemical Society (2025)
Closed Access
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Letian Song, Shenghua Gao, Bing Ye, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 87-109
Open Access | Times Cited: 19
Standing the test of COVID-19: charting the new frontiers of medicine
Simon Cauchemez, Giulio Cossu, Nathalie M. Delzenne, et al.
Frontiers in Science (2024) Vol. 2
Open Access | Times Cited: 5
“PROTAC” modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro
You Li, Nicky Hwang, Andrew Snedeker, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 102, pp. 129680-129680
Open Access | Times Cited: 3
Viral deubiquitinating proteases and the promising strategies of their inhibition
Vera Jannie Elisabeth van Vliet, Anuradha De Silva, Brian L. Mark, et al.
Virus Research (2024) Vol. 344, pp. 199368-199368
Open Access | Times Cited: 3
Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent Anti-Influenza Activity through Two Distinct Endonuclease Polymerase Acidic-Targeted Degradation Pathways
Xiaoyu Ma, Xueyun Wang, Feifei Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8791-8816
Closed Access | Times Cited: 3
Influenza A virus hemagglutinin: from classical fusion inhibitors to proteolysis targeting chimera-based strategies in antiviral drug discovery
Francisco Javier Hermoso-Pinilla, Aitor Valdivia, Marı́a-José Camarasa, et al.
(2024), pp. 85-116
Open Access | Times Cited: 3
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection
Lei Tian, Taotao Qiang, Xiuding Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115979-115979
Closed Access | Times Cited: 8
Synergizing Proteolysis-Targeting Chimeras and Nanoscale Exosome-Based Delivery Mechanisms for HIV and Antiviral Therapeutics
Nobendu Mukerjee, Swastika Maitra, Arabinda Ghosh, et al.
ACS Applied Nano Materials (2024) Vol. 7, Iss. 4, pp. 3499-3514
Closed Access | Times Cited: 2
Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality
Yang Zhou, Shujing Xu, Nerea López-Carrobles, et al.
Acta Materia Medica (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 6
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Yugendar R. Alugubelli, Jing Xiao, Kaustav Khatua, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
Nanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradation
Souvik Ghosal, Cara M. Robertus, Jeanette Wang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
PROTAC Beyond Cancer- Exploring the New Therapeutic Potential o f Proteolysis Targeting Chimeras
Ritesh P. Bhole, S. Patil, Harshad S. Kapare, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 23, pp. 2050-2073
Closed Access | Times Cited: 1
Harnessing PROTACs to combat H5N1 influenza: A new frontier in viral destruction
Nobendu Mukerjee, Swastika Maitra, Dattatreya Mukherjee, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 9
Open Access | Times Cited: 1
Targeted degrader technologies as prospective SARS-CoV-2 therapies
Rabia Khurshid, Joseph M. Schulz, Jiaming Hu, et al.
Drug Discovery Today (2023) Vol. 29, Iss. 1, pp. 103847-103847
Closed Access | Times Cited: 2
Nanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradation
Christopher A. Alabi, Souvik Ghosal, Cara M. Robertus, et al.
Research Square (Research Square) (2024)
Open Access
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery
Andrew A. Bolinger, Jun Li, Xuping Xie, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1023-1041
Closed Access
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
Narayanaperumal Pravin, Krzysztof Jóźwiak
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116837-116837
Open Access
Next-Generation Cancer Therapeutics: PROTACs and the Role of Heterocyclic Warheads in Targeting Resistance
Effat Omar, Rajendiran Rajesh, Pronoy Kanti Das, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117034-117034
Closed Access
Page 1 - Next Page

Scroll to top